DELAWARE
|
001-34079
|
11-3516358
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders
|
For
|
Against
|
Abstain
|
||
18,657,754
|
6,366,667
|
1,538,204
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
Certificate of Amendment of Amended and Restated Certificate of Incorporation of Rexahn Pharmaceuticals, Inc.
|
REXAHN PHARMACEUTICALS, INC.
|
|
Date: August 30, 2018
|
/s/ Douglas J. Swirsky
|
Douglas J. Swirsky
|
|
President and Chief Financial Officer
|
REXAHN PHARMACEUTICALS, INC.
|
||
By:
|
/s/ Peter Suzdak
|
|
Name:
|
Peter Suzdak
|
|
Title:
|
Chief Executive Officer
|